Jun 07,2018

DarioHealth Provides Update on Recently Launched iPhone 7, 8 and X Smart Glucose Meter in the U.S. Following FDA Clearance

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today it has experienced a successful launch of its iPhone® 7, 8 and X compatible Blood Glucose Monitoring System following FDA clearance.

PRODUCT

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 12,2018

Dexcom G5 Continuous Glucose Monitoring System Now Available on Mobile, Smart Devices for Medicare Patients with Diabetes

Dexcom announced today the U.S. Centers for Medicare & Medicaid Services (CMS) is updating its policy on mobile device compatibility for the Dexcom G5® CGM System. Available on iOS and Android, the Dexcom G5 is the first and only mobile-enabled CGM system for Medicare patients with diabetes that works to display and share real-time glucose activity.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 13,2018

Nemaura Medical Inc. Reports Full Year Financial Results

Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced financial results for the fiscal year ended March 31, 2018. Research and development expenses were approximately $994,000 and $1.035 million for the years ended March 31, 2018 and 2017, respectively. This amount related to clinical trials and improvements made to the sugarBEAT® device, and expenditures included sub-contractor activities, and consultancy fees and wages.

View Analyst & Ambassador Comments
Go to original news
Jun 18,2018

FDA grants DreaMed's de novo request for device-friendly diabetes software

The FDA has granted Isreal-based DreaMed Diabetes a de novo request for its artificial intelligence-powered software for providers managing patients with Type 1 diabetes. Advisor Pro received a CE mark in February, and according to the company is being used by “leading clinical centers” in both the EU and the US.

REGULATORY FDA

#dtx

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 19,2018

Medtronic Introduces Updated iPro(TM)2 myLog App with FoodPrint(TM) Report Enhancing Diagnostic CGM for People with Diabetes

Medtronic (NYSE:MDT), the global leader in medical technology, today announced the availability of the updated iPro(TM)2 myLog app with FoodPrint(TM) Report. The iPro2 myLog app offers a simple way for clinics to import patients' logged data during their professional iPro2 continuous glucose monitoring (CGM) evaluation.

PRODUCT

#mobile app

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 19,2018

Insulet to Unveil New Omnipod® DASH™ System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it will showcase its recently FDA cleared Omnipod DASHTM Insulin Management System (Omnipod DASH System), during the American Diabetes Association (ADA) 78th Scientific Sessions at the Orange County Convention Center in Orlando, Florida June 22-25, 2018.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 19,2018

Medtronic Announces Scientific Data Presentations at the American Diabetes Association 78th Scientific Sessions Meeting

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the 78th Scientific Sessions of the American Diabetes Association, in Orlando, June 22-26. A significant portion of the scientific data being presented focuses on Medtronic's insulin pump systems, including the MiniMed 670G system, the world's first hybrid closed-loop system.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 20,2018

Brighter is negotiating with Indonesian sales partners

Brighter is now in a number of active discussions with the majority of Indonesian sales partners, in addition to Indosat Ooredoo, regarding the sale of Actiste, Brighter's unique service for diabetics, in Indonesia. The negotiations concern rights regarding sales to a wider range of sales channels, including insurance companies and healthcare producers in the region.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 21,2018

Tandem Diabetes Care Announces FDA Approval of t:slim X2 Insulin Pump with Basal-IQ Technology

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced U.S. Food and Drug Administration (FDA) approval of the t:slim X2™ Insulin Pump with Basal-IQ™ technology, a predictive low glucose suspend (PLGS) feature designed to help reduce the frequency and duration of low glucose events (hypoglycemia).

REGULATORY FDA

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 21,2018

Medtronic Receives FDA Approval of New Pediatric Indication for the MiniMed(TM) 670G Hybrid Closed Loop System in Children Ages 7-13

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of the MiniMed 670G system in patients with type 1 diabetes seven years of age and older.

REGULATORY FDA

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES